{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:27:00Z","timestamp":1793212020970,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jhep.2024.08.015","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T17:20:37Z","timestamp":1725124837000},"page":"446-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Predictors of hepatic flares after nucleos(t)ide analogue cessation \u2013 Results of a global cohort study (RETRACT-B study)"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2746-1643","authenticated-orcid":false,"given":"Edo J.","family":"Dongelmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1530-5950","authenticated-orcid":false,"given":"Grishma","family":"Hirode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-7941","authenticated-orcid":false,"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8658-4742","authenticated-orcid":false,"given":"Arno","family":"Furquim d'Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"van Hees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-6591","authenticated-orcid":false,"given":"Margarita","family":"Papatheodoridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-9389","authenticated-orcid":false,"given":"Grace L.H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7687-4036","authenticated-orcid":false,"given":"Sylvia M.","family":"Brakenhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7790-1611","authenticated-orcid":false,"given":"Henry L.Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-1764","authenticated-orcid":false,"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-4060","authenticated-orcid":false,"given":"George V.","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0572-8741","authenticated-orcid":false,"given":"Thomas","family":"Vanwolleghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-7725","authenticated-orcid":false,"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8984-5103","authenticated-orcid":false,"given":"Yao-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan J.","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Juei","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.08.015_bib1","series-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016\u20132021: actions for impact","year":"2021"},{"issue":"1","key":"10.1016\/j.jhep.2024.08.015_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cld.728","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"12","author":"Terrault","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"2","key":"10.1016\/j.jhep.2024.08.015_bib3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.08.015_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.jhep.2024.08.015_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3350\/cmh.2016.0045","article-title":"The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy","volume":"22","author":"Varbobitis","year":"2016","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.08.015_bib6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.08.015_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/kjm2.12518","article-title":"Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an \"option\" to an \"active recommendation\"","volume":"38","author":"Liaw","year":"2022","journal-title":"Kaohsiung J Med Sci"},{"issue":"4","key":"10.1016\/j.jhep.2024.08.015_bib8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients","volume":"15","author":"Kao","year":"2021","journal-title":"Hepatol Int"},{"issue":"10","key":"10.1016\/j.jhep.2024.08.015_bib9","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"214","author":"H\u00f6ner Zu Siederdissen","year":"2016","journal-title":"J\u00a0Infect Dis"},{"issue":"10","key":"10.1016\/j.jhep.2024.08.015_bib10","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/infdis\/jiy097","article-title":"Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss","volume":"217","author":"Zimmer","year":"2018","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.jhep.2024.08.015_bib11","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","article-title":"Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"69","author":"Rinker","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.08.015_bib12","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A\u00a0multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"van B\u00f6mmel","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2024.08.015_bib13","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.14309\/ajg.0000000000002125","article-title":"Randomized trial of tenofovir with or without peginterferon alfa followed by protocolized treatment withdrawal in adults with chronic hepatitis B","volume":"118","author":"Terrault","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jhep.2024.08.015_bib14","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1016\/j.cgh.2020.12.005","article-title":"Prediction of sustained response\u00a0after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE)","volume":"20","author":"Sonneveld","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.08.015_bib15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.jhep.2024.08.015_bib16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir Ther"},{"issue":"4","key":"10.1016\/j.jhep.2024.08.015_bib17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","article-title":"Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study","volume":"64","author":"Seto","year":"2015","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jhep.2024.08.015_bib18","article-title":"Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.08.015_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1037527","article-title":"Systematic review: clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis","volume":"10","author":"Yao","year":"2022","journal-title":"Front Public Health"},{"issue":"9","key":"10.1016\/j.jhep.2024.08.015_bib20","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.14309\/ajg.0000000000002203","article-title":"Incidence of hepatic decompensation after nucleos(t)ide analogue withdrawal: results from a large, international, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study)","volume":"118","author":"Hirode","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"11\u201312","key":"10.1016\/j.jhep.2024.08.015_bib21","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/17474124.2022.2156338","article-title":"Hepatitis B flare: the good, the bad and the ugly","volume":"16","author":"Liaw","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.jhep.2024.08.015_bib22","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1053\/j.gastro.2018.03.066","article-title":"HBsAg kinetics in retreatment decision for off-therapy hepatitis B flare in HBeAg-negative patients","volume":"154","author":"Liaw","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2024.08.015_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jac\/dkab360","article-title":"Highly significant differences in HBsAg kinetics among patients with two types of hepatitis B flare, with and without retreatment","volume":"77","author":"Jeng","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jhep.2024.08.015_bib24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.jhep.2024.08.015_bib25","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/jvh.13742","article-title":"Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B","volume":"29","author":"Liem","year":"2022","journal-title":"J\u00a0Viral Hepat"},{"issue":"1","key":"10.1016\/j.jhep.2024.08.015_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jmii.2022.06.002","article-title":"End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares\u00a0in\u00a0chronic hepatitis B patients","volume":"56","author":"Brakenhoff","year":"2022","journal-title":"J\u00a0Microbiol Immunol Infect"},{"issue":"3","key":"10.1016\/j.jhep.2024.08.015_bib27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/liv.15140","article-title":"Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies","volume":"42","author":"Liu","year":"2022","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jhep.2024.08.015_bib28","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/biomedicines11030752","article-title":"Chronic hepatitis B relapse rates after cessation of tenofovir alafenamide and entecavir therapy","volume":"11","author":"Huang","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jhep.2024.08.015_bib29","series-title":"IBM Corp. IBM SPSS statistics for windows, version 28","year":"2021"},{"key":"10.1016\/j.jhep.2024.08.015_bib30","series-title":"R: a language and environment for statistical computing","year":"2022"},{"issue":"7","key":"10.1016\/j.jhep.2024.08.015_bib31","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.14309\/ajg.0000000000002176","article-title":"Withdrawal of long-term nucleotide analogue therapy in chronic hepatitis B: outcomes from the withdrawal phase of the HBRN immune active treatment trial","volume":"118","author":"Feld","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jhep.2024.08.015_bib32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/apt.17614","article-title":"Severe hepatitis B flares with hepatic\u00a0decompensation after withdrawal of nucleos(t)ide analogues: a population-based cohort study","volume":"58","author":"Hsu","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jhep.2024.08.015_bib33","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.cgh.2022.08.021","article-title":"The Role of Off-Therapy Viral Kinetics in the Timing and Severity of Flares in Hepatitis B e Antigen-Negative Patients","volume":"21","author":"Liu","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.08.015_bib34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/liv.14330","article-title":"The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B","volume":"40","author":"Wong","year":"2020","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.jhep.2024.08.015_bib35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2022.03.006","article-title":"A\u00a0case of HBV-induced liver failure in the REEF-2 phase II trial: implications for finite treatment strategies in HBV 'cure'","volume":"77","author":"Agarwal","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"24","key":"10.1016\/j.jhep.2024.08.015_bib36","first-page":"7565","article-title":"Hepatitis Flares or Hepatic Decompensation after Discontinuation of Tenofovir Disoproxil Fumarate and Entecavir in Non-Cirrhotic Hepatitis B e Antigen-Negative Patients","volume":"12","author":"Huang","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"10.1016\/j.jhep.2024.08.015_bib37","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/jvh.12851","article-title":"The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients","volume":"25","author":"Chen","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"issue":"6","key":"10.1016\/j.jhep.2024.08.015_bib38","article-title":"Utility of novel viral and immune markers in predicting HBV treatment endpoints: a systematic review of treatment discontinuation studies","volume":"5","author":"Zeng","year":"2023","journal-title":"JHEP Rep"},{"issue":"9","key":"10.1016\/j.jhep.2024.08.015_bib39","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00535-021-01812-0","article-title":"HBeAg-positive patients with HBsAg < 100 IU\/ml and\u00a0negative HBV RNA have lower risk of virological relapse after nucleos(t)ide\u00a0analogues cessation","volume":"56","author":"Xie","year":"2021","journal-title":"J\u00a0Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhep.2024.08.015_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12072-021-10159-w","article-title":"Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation","volume":"15","author":"Kuo","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.08.015_bib41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijid.2019.07.036","article-title":"Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: a meta-analysis","volume":"86","author":"Liu","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.jhep.2024.08.015_bib42","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12876-023-02852-x","article-title":"Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation","volume":"23","author":"Xie","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhep.2024.08.015_bib43","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.cgh.2022.07.005","article-title":"Differential relapse patterns after discontinuation of entecavir vs tenofovir disoproxil fumarate in chronic hepatitis B","volume":"21","author":"Choi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.08.015_bib44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.16968","article-title":"Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels","volume":"56","author":"Hall","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.jhep.2024.08.015_bib45","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/jgh.15966","article-title":"A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: an observational study","volume":"37","author":"Peng","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2024.08.015_bib46","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jfma.2023.02.002","article-title":"Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy","volume":"122","author":"Lin","year":"2023","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"10.1016\/j.jhep.2024.08.015_bib47","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.gastro.2023.09.033","article-title":"HBV DNA and HBsAg levels at 24 Weeks off-treatment predict clinical relapse and HBsAg loss in HBeAg-negative patients who discontinued antiviral therapy","volume":"166","author":"Sonneveld","year":"2024","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2024.08.015_bib48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/hep.31525","article-title":"Hepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: to retreat or not to retreat","volume":"73","author":"Liaw","year":"2021","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824024930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824024930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T16:36:57Z","timestamp":1739551017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824024930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0168827824024930"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.08.015","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of hepatic flares after nucleos(t)ide analogue cessation \u2013 Results of a global cohort study (RETRACT-B study)","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}